Stocks and Investing Stocks and Investing
Mon, June 26, 2023
Fri, June 23, 2023
Thu, June 22, 2023
Wed, June 21, 2023

Charles Duncan Reiterated (XENE) at Buy and Held Target at $58 on, Jun 21st, 2023


Published on 2024-10-28 04:26:57 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Reiterated "Xenon Pharmaceuticals Inc." (XENE) at Buy and Held Target at $58 on, Jun 21st, 2023.

Charles has made no other calls on XENE in the last 4 months.



There are 5 other peers that have a rating on XENE. Out of the 5 peers that are also analyzing XENE, 0 agree with Charles's Rating of Hold.



These are the ratings of the 5 analyists that currently disagree with Charles


  • Yatin Suneja of "Guggenheim" Reiterated at Strong Buy and Held Target at $49 on, Thursday, June 15th, 2023
  • Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $47 on, Wednesday, May 10th, 2023
  • Tessa Romero of "JP Morgan" Maintained at Buy with Increased Target to $55 on, Tuesday, April 25th, 2023
  • Serge Belanger of "Needham" Reiterated at Strong Buy and Held Target at $50 on, Friday, April 21st, 2023
  • Brian Abrahams of "RBC Capital" Reiterated at Buy and Held Target at $51 on, Wednesday, March 22nd, 2023